产碳青霉烯酶与非产碳青霉烯酶肠杆菌目细菌获得的风险因素:病例对照研究
在以色列Rambam Health Care Campus开展平行1:2匹配病例对照研究,纳入2014年1月至2017年6月院内获得碳青霉烯酶产肠杆菌目(CPE)或非产碳青霉烯酶碳青霉烯耐药肠杆菌目(non-CP-CRE)的成人患者。结果显示CPE获得与高CRE定植压力相关(aOR 2.6,95%CI 1.69-4.02),non-CP-CRE获得与碳青霉烯治疗天数相关(每日aOR 1.07,95%CI 1.03-1.11)。
要点
- 高CRE定植压力与CPE获得相关(aOR 2.6,95%CI 1.69-4.02)。
- 碳青霉烯治疗天数与non-CP-CRE获得相关(每日aOR 1.07,95%CI 1.03-1.11)。
- CPE流行病学调查中更常识别到源患者(44.6% vs 28.1%,p 0.017)。
核心结论
- CPE获得与水平传播相关,而non-CP-CRE获得与碳青霉烯暴露相关。
- 获得驱动因素的差异要求采取针对性的感染预防措施。
研究设计与样本
- 在以色列Rambam Health Care Campus开展平行1:2匹配病例对照研究,时间范围为2014年1月至2017年6月。
- 病例为所有院内获得CPE或non-CP-CRE的成人,对照为CRE筛查阴性且按年龄、住院科室及CRE筛查前90天内住院天数匹配的住院患者。
- 共纳入1058例患者:278例CPE病例匹配556例对照,75例non-CP-CRE病例匹配149例对照。
- 暴露因素为高CRE定植压力(获得前同科室CRE携带者比例高于中位数)和碳青霉烯暴露(以治疗天数评估)。
- 采用条件logistic回归分析CPE和non-CP-CRE。
主要发现
- 高CRE定植压力与CPE获得相关(aOR 2.6;95%CI 1.69-4.02)。
- 碳青霉烯治疗天数与CPE获得不相关(每增加1天aOR 1.004;95%CI 0.98-1.03)。
- 碳青霉烯治疗天数与non-CP-CRE获得显著相关(每日aOR 1.07;95%CI 1.03-1.11)。
- CPE流行病学获得调查中源患者识别率显著高于non-CP-CRE(107/240,44.6% vs 18/64,28.1%;p 0.017)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We aimed to assess the association between carbapenem-resistant Enterobacterales (CRE) colonization pressure and carbapenem exposure and acquisition of carbapenemase-producing Enterobacterales (CPE) and non-carbapenemase-producing carbapenem-resistant Enterobacterales (non-CP-CRE). METHODS: We conducted a parallel 1:2 matched case-control study at Rambam Health Care Campus, Israel, from January 2014 to June 2017. The cases included all adults who acquired CPE or non-CP-CRE in hospital. The controls were hospitalized patients who were negative for CRE on screening and matched by age, hospitalization division and the number of hospitalization days 90 days prior to CRE screening. The exposures of interest were high CRE colonization pressure, defined as a higher-than-median proportion of CRE carriers in the concurrent patient's department before acquisition, and carbapenem exposure, assessed as days of treatment. Conditional logistic regression was used for analyses of CPE and non-CP-CRE. RESULTS: In total, 1058 patients were included: 278 CPE and 75 non-CP-CRE cases, matched to 556 and 149 controls, respectively. High CRE colonization pressure was associated with CPE acquisition (adjusted odds ratio [aOR], 2.6; 95% CI, 1.69-4.02); however, the duration of carbapenem treatment was not (aOR, 1.004; 95% CI, 0.98-1.03; 1-day increment). The duration of carbapenem treatment was significantly associated with non-CP-CRE acquisition (aOR per day, 1.07; 95% CI, 1.03-1.11). A source patient was identified significantly more frequently in epidemiological acquisition investigations of CPE than in those of non-CP-CRE (107/240, 44.6% vs. 18/64, 28.1%, respectively; p 0.017). CONCLUSIONS: CPE acquisition was associated with horizontal transmission, whereas non-CP-CRE was associated with carbapenem exposure. Differences in the drivers of acquisition mandate tailored infection prevention efforts.
引用
- Hassoun-Kheir N, Hussein K, Karram M, et al. Risk factors for acquisition of carbapenemase-producing versus non-carbapenemase-producing enterobacterales: a case-control study. Clin Microbiol Infect. 2023. PMID: 36641053. doi:10.1016/j.cmi.2023.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。